3-氨基噻吩[2,3-B]吡啶-2-羧酸 | 58327-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: 3-氨基噻吩[2,3-B]吡啶-2-羧酸
• 英文名称: 3-aminothieno[2,3-b]pyridine-2-carboxylic acid
• CAS: 58327-75-6
• 化学式: C₈H₆N₂O₂S
• mdl: MFCD03783349
• 分子量: 194.214
• InChiKey: HGKGNTBBCCWIRD-UHFFFAOYSA-N

物化性质

• 熔点：
  202 °C
• 沸点：
  453.3±45.0 °C(Predicted)
• 密度：
  1.604±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302

SDS

Name:	3-Aminothieno[2 3-b]pyridine-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	58327-75-6

Section 1 - Chemical Product MSDS Name:3-Aminothieno[2 3-b]pyridine-2-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
58327-75-6	3-Aminothieno[2,3-b]pyridine-2-carboxy	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 58327-75-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: green
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 278 - 279 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6N2O2S
Molecular Weight: 194.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 58327-75-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Aminothieno[2,3-b]pyridine-2-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 58327-75-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 58327-75-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 58327-75-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基噻吩[2,3-B]吡啶-2-羧酸 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 5H-pyrido[3‘‘,2‘‘:4‘,5‘]thieno[3‘,2‘:4,5]pyrimido[2,1-a]isoquinoline-8(6H)-one
  参考文献：
  名称：

  A simple heterocyclic fusion reaction and its application for expeditious syntheses of rutaecarpine and its analogs

  摘要：

  DOI：

  10.1016/j.tetlet.2014.04.120
• 作为产物：
  描述：

  2-磺酰基烟腈 在 氢氧化钾 作用下， 生成 3-氨基噻吩[2,3-B]吡啶-2-羧酸
  参考文献：
  名称：

  Guerrera; Siracusa; Tornetta, Farmaco, Edizione Scientifica, 1976, vol. 31, # 1, p. 21 - 30

  摘要：

  DOI：

文献信息

• [EN] cGAS ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DU CGAS
  申请人：IMMUNE SENSOR LLC

  公开号：WO2017176812A1

  公开（公告）日：2017-10-12

  Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

  揭示了一种新型化合物的化学式（I），这些化合物是cGAS拮抗剂，涉及到这些化合物的制备方法、包含这些化合物的药物组合物，以及它们在医学治疗中的应用。
• Design, Synthesis, and Structure–Activity Relationship Studies of a Series of [4-(4-Carboxamidobutyl)]-1-arylpiperazines: Insights into Structural Features Contributing to Dopamine D3 versus D2 Receptor Subtype Selectivity
  作者：Subramaniam Ananthan、Surendra K. Saini、Guangyan Zhou、Judith V. Hobrath、Indira Padmalayam、Ling Zhai、J. Robert Bostwick、Tamara Antonio、Maarten E. A. Reith、Shea McDowell、Eunie Cho、Leah McAleer、Michelle Taylor、Robert R. Luedtke

  DOI：10.1021/jm500801r

  日期：2014.8.28

  receptors suggest that interactions at the extracellular end of TM7 contribute to the D3R versus D2R selectivity of these ligands. Molecular insights from this study could potentially enable rational design of potent and selective D3R ligands.

  多巴胺 D3 受体 (D3R) 的拮抗剂和部分激动剂调节剂已成为治疗药物滥用和神经精神疾病的有希望的疗法。然而，由于 D3R 和多巴胺 D2 受体 (D2R) 之间的高度序列同源性，开发对 D3 受体具有选择性的药物样先导化合物一直具有挑战性。在这项工作中，我们合成了一系列包含氮杂芳族单元的酰基氨基丁基哌嗪，并评估了它们对 D3 和 D2 受体的结合和功能活性。对接研究和对一组嵌合和突变受体的评估结果表明，TM7 细胞外末端的相互作用有助于这些配体的 D3R 与 D2R 选择性。
• [EN] TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS<br/>[FR] ANTAGONISTES ALPHA-1-ADRENERGIQUES D'HEXAHYDROBENZEISOINDOL TRICYCLIQUE SUBSTITUE
  申请人：ABBOTT LABORATORIES

  公开号：WO1996022992A1

  公开（公告）日：1996-08-01

  (EN) The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an $g(a)-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are $g(a)-1 antagonist compositions and a method for antagonizing $g(a)-1 receptors and treating BPH.(FR) La présente invention concerne un composé, ainsi que ses sels acceptables sur le plan pharmaceutique, correspondant à la formule (I) où W est un système de noyau hétérocyclique tricyclique. Ce composé est un antagoniste $g(a)-1 adrénergique utile dans le traitement de l'hyperplasie prostatique bénigne. Cette invention concerne également des compositions à base d'antagoniste $g(a)-1 ainsi qu'un procédé visant à rendre antagonistes des récepteurs $g(a)-1, et utilisé dans le traitement de l'hyperplasie prostatique bénigne.

  本发明涉及化合物(I)及其在药学上可接受的盐，其中W是三环杂环环系统；该化合物是$g(a)-1肾上腺素受体拮抗剂，用于治疗BPH；此外还揭示了$g(a)-1拮抗剂组合物以及拮抗$g(a)-1受体和治疗BPH的方法。
• Bicyclic heteroaromatic compounds as kinase inhibitors
  申请人：Brookings Christopher Daniel

  公开号：US20060025428A1

  公开（公告）日：2006-02-02

  A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 6-oxo-6,7-dihydrothieno[2,3->b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.

  一系列5-6个融合环的双环杂环芳香衍生物，特别是基于6-氧代-6,7-二氢噻吩[2,3->b]吡啶环系统，作为p38激酶抑制剂，在医学上有用，例如在治疗和/或预防免疫或炎症性疾病方面。
• Acyclic 1,3-Diamine And Uses Therefor
  申请人：Casillas N. Linda

  公开号：US20070259965A1

  公开（公告）日：2007-11-08

  This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I or pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein: R 1 is aryl optionally substituted with CN, NO 2 , halogen or H; R 2 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocycloalkyl; R 3 is H, OH, O—C 1 -C 6 alkyl, SH, S—C 1 -C 6 alkyl, or F; R 4 is H, C 1 -C 6 alkyl R 5 is iso-butyl, cyclohexylmethyl, or cyclopentylmethyl; and R 6 is aryl, heteroaryl.

  本发明涉及一种新型化合物，可用于治疗与TRPV4通道受体相关的疾病。更具体地说，本发明涉及按照公式I或其药学上可接受的盐、水合物或溶剂化物所替代的氨基-氮杂环化合物，其中：R1是芳基，可选用CN、NO2、卤素或H进行取代；R2是H、C1-C6烷基、C3-C7环烷基或C3-C7杂环烷基；R3是H、OH、O-C1-C6烷基、SH、S-C1-C6烷基或F；R4是H或C1-C6烷基；R5是异丁基、环己基甲基或环戊基甲基；R6是芳基或杂芳基。